Skip to main content
BloomShieldShielded by care. Empowered to bloom.

Evidence-led screening guide

PSA Test

A PSA test measures prostate-specific antigen in the blood. It can support assessment and informed decisions, but a raised result does not diagnose prostate cancer and a result within the expected range cannot completely rule it out.

Read current NHS PSA test guidance (external link, opens in a new tab)Read Our Guide
A Black man reading plain health information in a warm home setting

Quick guide

PSA Test at a Glance

What PSA stands for
Prostate-specific antigen, a protein made by the prostate.
What the test is
A blood test that measures the amount of PSA in the blood.
Why it may be offered
To help assess symptoms or risk, or monitor a known prostate condition or treatment.
What a raised result means
PSA is higher than expected in that clinical context. It does not diagnose prostate cancer.
What a normal result means
It may reduce concern, but it does not completely rule prostate cancer out.
Screening position
There is no general NHS population-screening programme for prostate cancer. The UK National Screening Committee recommends PSA testing every 2 years for men aged 45–61 with a pathogenic BRCA2 variant and a relevant family history. How eligible men are identified and invited may continue to develop.

Last reviewed:

Next review due:

2. What Is PSA?

PSA stands for prostate-specific antigen. It is a protein made by cells in the prostate and is present in semen and in small amounts in blood.

PSA levels can change for several reasons. Prostate cancer can raise PSA, but so can benign prostate enlargement, inflammation, infection and recent activities or procedures that affect the prostate.

3. What Is a PSA Test?

A PSA test is a laboratory blood test. It measures the concentration of PSA in a blood sample and provides one piece of information for a clinician to interpret alongside symptoms, age, examination findings, personal risk and previous results.

PSA is prostate-specific, not cancer-specific. The test cannot by itself confirm or exclude prostate cancer.

4. Why Might a PSA Test Be Offered?

A clinician may offer or discuss PSA testing when someone has symptoms that could relate to the prostate, has particular risk factors, or is being monitored for a known prostate condition or after treatment.

Men and anyone with a prostate can ask a GP about PSA testing. This should lead to a balanced discussion rather than an automatic test. The possible benefits and harms depend on the person's circumstances and preferences.

Population and Targeted Screening Are Different

There is no general NHS population-screening programme for prostate cancer. The UK National Screening Committee has recommended targeted screening every 2 years for a specific high-risk group: men aged 45–61 with a pathogenic BRCA2 variant and a relevant family history of breast, ovarian, pancreatic or prostate cancer. It does not recommend targeted screening for other risk groups.

Ministers in England have agreed to implement a nationally managed approach for this defined group. How eligible men are identified and invited may continue to develop, so people with a known genetic variant should follow advice from their genetics or clinical team and current official NHS guidance.

5. How the Blood Test Is Performed

A healthcare professional takes a blood sample from a vein, usually in the arm. The sample is sent to a laboratory and the requesting service explains how the result will be communicated.

Current NHS guidance advises avoiding ejaculation, anal sex, vigorous exercise and cycling for 48 hours before the test because these can raise PSA temporarily. Tell the clinician about urinary or prostate infections, recent prostate procedures and medicines, and follow the instructions from the service arranging the test.

6. What a PSA Result May Mean

PSA Higher Than Expected

A raised result does not diagnose prostate cancer. The clinician may repeat the test, assess for infection or inflammation, examine the prostate, review risk factors or refer for investigations such as MRI. NICE advises against deciding on biopsy from PSA alone.

PSA Within the Expected Range

This may make prostate cancer less likely in the current context, but it does not completely rule it out. Persistent symptoms or ongoing clinical concern may still need review.

Changes Over Time

When PSA is monitored, the pattern over time may be considered alongside other clinical information. Do not compare your result with a single online threshold because interpretation varies with context and pathway.

7. Benefits of PSA Testing

  • It is a straightforward blood test that can help identify when further assessment may be appropriate.
  • It may help detect some prostate cancers before they cause symptoms.
  • It can support monitoring of a known prostate condition or response after treatment.
  • Used with other clinical information, it can contribute to shared decisions about MRI and other investigations.

8. Limitations and Possible Harms

  • False positive: a raised PSA may lead to anxiety and further tests even though cancer is not present.
  • False negative: some prostate cancers do not produce a raised PSA.
  • Overdiagnosis: testing can identify a slow-growing cancer that would never have caused harm, but the diagnosis may lead to monitoring or treatment.
  • Further investigations have trade-offs: MRI and biopsy can create uncertainty, discomfort or complications.
  • Treatment can cause lasting side effects: finding a low-risk cancer may expose someone to treatment harms without a clear benefit.

9. PSA Testing and Informed Choice

There is no single correct choice for every person. A useful discussion considers why the test is being considered, symptoms, age, ethnicity, family history, known genetic risk, general health, preferences and willingness to have further investigations.

Ask what a raised or normal result would change, what follow-up could involve and how uncertainty will be managed. Choosing not to have a PSA test now does not prevent you from seeking advice later if symptoms or circumstances change.

10. Prostate Symptoms and When to Contact Your GP

Contact your GP about urinary changes such as difficulty starting or maintaining urine flow, needing to urinate more often, blood in urine, erectile difficulties, unexplained pain or other changes that concern you. These symptoms often have causes other than cancer, including benign prostate enlargement.

A PSA test is only one possible part of assessment. Do not use a previous PSA result as a reason to delay medical advice if symptoms persist, change or worsen.

Read current NHS prostate cancer symptom guidance (external link, opens in a new tab)

11. Common Myths About PSA

“A High PSA Means I Have Prostate Cancer.”

No. Several non-cancer conditions and recent activities can raise PSA. Further assessment is needed to understand the result.

“A Normal PSA Rules Out Prostate Cancer.”

No. Some prostate cancers do not cause a raised PSA.

“Every Man Over 50 Should Be Tested Regularly.”

No blanket recommendation applies. The UK NSC does not recommend general-population PSA screening. Testing should follow informed discussion and current clinical guidance.

“The New Targeted Programme Is Screening for Everyone.”

No. The recommendation is limited to PSA testing every 2 years for men aged 45–61 who have both a pathogenic BRCA2 variant and a relevant family history of breast, ovarian, pancreatic or prostate cancer. It does not extend to all men with a family history, all Black men, BRCA1 carriers or the wider male population.

12. Frequently Asked Questions

Does a high PSA mean prostate cancer?
No. PSA can be raised by prostate enlargement, inflammation, infection and other factors. A raised result needs interpretation in context and may lead to repeat testing, examination, MRI or other assessment.
Can a normal PSA miss prostate cancer?
Yes. A PSA result within the expected range does not completely rule out prostate cancer. Contact your GP if symptoms persist, change or concern you.
Can I ask my GP for a PSA test?
Men and anyone with a prostate can ask a GP about PSA testing. The GP should discuss your symptoms, personal risk and the possible benefits and harms before deciding with you whether testing is appropriate.
Why is there no general-population PSA screening programme?
The UK National Screening Committee concluded that screening is more likely to cause more harm than good across the general population. It recommends PSA testing every 2 years only for men aged 45–61 who have both a pathogenic BRCA2 variant and a relevant family history of breast, ovarian, pancreatic or prostate cancer. How eligible men are identified and invited may continue to develop.
What can affect my PSA level?
Prostate enlargement, inflammation or infection can raise PSA. Ejaculation, anal sex, vigorous exercise and cycling shortly before the test can also affect the result. Follow the preparation advice from the service arranging your test.
Do I need to prepare before the blood test?
Current NHS guidance advises avoiding ejaculation, anal sex, vigorous exercise and cycling for 48 hours before a PSA test. Tell the clinician about infections, recent prostate procedures and medicines, and follow their instructions.
What happens if my PSA is raised?
Your clinician will consider the result with your age, symptoms, examination and risk factors. They may repeat the test, treat a possible infection or refer you for investigations such as MRI. A raised PSA alone is not a diagnosis.
Should every man over 50 have a PSA test?
No blanket recommendation applies. PSA testing involves trade-offs, so the decision should be based on informed discussion of individual risk, preferences, possible benefits and possible harms.
What if I have urinary symptoms?
Contact your GP for assessment rather than relying on a PSA test alone. Urinary symptoms often have non-cancer causes, but they still need appropriate clinical review.

13. Evidence and References

These primary sources reflect the current NHS test information, the March 2026 UK screening recommendation, England's targeted-programme position and NICE diagnostic guidance.

14. Official NHS Resources

Use these sources for current access, preparation, screening-policy and follow-up information. Arrangements differ across UK nations.

Read the Family History and Inherited Risk and Cancer Symptoms guides for related context.

15. How BloomShield Helps

Balanced, accessible information supports informed choice without turning a complex test into an unofficial screening recommendation.

ScreenAccess™

identifies and helps address practical, social and service barriers to screening access.

ScreenConnect™

supports navigation, coordination and continuity across screening and care pathways.

Work with BloomShield to improve informed access